Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Talquetamab with or without Teclistamab for the Treatment of Newly Diagnosed Multiple Myeloma, ROTATE Trial

Trial Status: active

This phase II trial tests the effect of talquetamab followed by teclistamab, if necessary, in treating patients with newly diagnosed multiple myeloma that have been treated with induction therapy and an autologous transplant and still have signs of disease in the bone marrow (minimal residual disease [MRD]). Talquetamab binds to a protein called CD3, which is found on T cells (a type of white blood cell), and to a protein called GPRC5D, which is found on myeloma cells and some other types of cells. This may help the immune system kill cancer cells. Talquetamab is a type of bispecific T-cell engager. Teclistamab is a bispecific antibody that can bind to two different antigens at the same time. Teclistamab binds to B-cell maturation antigen, a protein found on some B-cells and myeloma cells, and CD3 on T-cells (a type of white blood cell) and may interfere with the ability of cancer cells to grow and spread. Giving talquetamab followed by teclistamab, if necessary, may reduce the amount of cancer left and improve long-term survival rates in patients with multiple myeloma after their initial treatment.